Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Grillo-López

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Seminars in Oncology|February 28, 2001
Rituximab: an insider's historical perspectiveA J Grillo-López
Seminars in Oncology|November 24, 1999
Rituximab in indolent lymphoma: the single-agent pivotal trialP McLaughlin, F B Hagemeister, A J Grillo-López
Current Pharmaceutical Biotechnology|July 27, 2001
Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphomaC A White, J R Berlfein, A J Grillo-López
Investigational New Drugs|January 1, 1986
CI-921: an analog of amsacrine with experimental activity against solid tumorsW R Grove, L W DeLap, A J Grillo-López
Annual Review of Medicine|February 13, 2001
Antibody-targeted immunotherapy for treatment of malignancyC A White, R L Weaver, A J Grillo-López
Investigational New Drugs|January 1, 1985
A phase I trial of ametantrone acetate (NSC-287513)R A Gams, F Ostroy, J F Bender, et al.
Oncology (Williston Park, N.Y.)|January 6, 1999
Clinical status and optimal use of rituximab for B-cell lymphomasP McLaughlin, C A White, A J Grillo-López, et al.
Leukemia & Lymphoma|October 27, 2006
Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximabM S Czuczman, A J Grillo-López, B Alkuzweny, et al.
Leukemia|July 30, 2003
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacyL E van der Kolk, A J Grillo-López, J W Baars, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1986
Amsacrine-associated cardiotoxicity: an analysis of 82 casesR B Weiss, A J Grillo-López, S Marsoni, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Seminars in Oncology|February 28, 2001
Rituximab: an insider's historical perspectiveA J Grillo-López
Seminars in Oncology|November 24, 1999
Rituximab in indolent lymphoma: the single-agent pivotal trialP McLaughlin, F B Hagemeister, A J Grillo-López
Current Pharmaceutical Biotechnology|July 27, 2001
Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphomaC A White, J R Berlfein, A J Grillo-López
Investigational New Drugs|January 1, 1986
CI-921: an analog of amsacrine with experimental activity against solid tumorsW R Grove, L W DeLap, A J Grillo-López
Annual Review of Medicine|February 13, 2001
Antibody-targeted immunotherapy for treatment of malignancyC A White, R L Weaver, A J Grillo-López
Investigational New Drugs|January 1, 1985
A phase I trial of ametantrone acetate (NSC-287513)R A Gams, F Ostroy, J F Bender, et al.
Oncology (Williston Park, N.Y.)|January 6, 1999
Clinical status and optimal use of rituximab for B-cell lymphomasP McLaughlin, C A White, A J Grillo-López, et al.
Leukemia & Lymphoma|October 27, 2006
Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximabM S Czuczman, A J Grillo-López, B Alkuzweny, et al.
Leukemia|July 30, 2003
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacyL E van der Kolk, A J Grillo-López, J W Baars, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1986
Amsacrine-associated cardiotoxicity: an analysis of 82 casesR B Weiss, A J Grillo-López, S Marsoni, et al.
Pageof 4